Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ Jr; ACTG A5262 Team.

AIDS. 2011 Nov 13;25(17):2113-22. doi: 10.1097/QAD.0b013e32834bbaa9.

2.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
3.

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

Boffito M, Miralles D, Hill A.

HIV Clin Trials. 2008 Nov-Dec;9(6):418-27. doi: 10.1310/hct0906-418. Review. Erratum in: HIV Clin Trials. 2009 Mar-Apr;10(2):vi. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
19203907
4.

Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.

Menshawy A, Ismail A, Abushouk AI, Ahmed H, Menshawy E, Elmaraezy A, Gadelkarim M, Abdel-Maboud M, Attia A, Negida A.

Arch Virol. 2017 Aug;162(8):2181-2190. doi: 10.1007/s00705-017-3346-9. Epub 2017 Mar 30. Review.

PMID:
28361290
5.

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR.

AIDS. 2012 Jan 14;26(2):185-92. doi: 10.1097/QAD.0b013e32834e9d7d. Review.

6.

Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.

White KL, Raffi F, Miller MD.

Viruses. 2014 Jul 22;6(7):2858-79. doi: 10.3390/v6072858. Review.

7.

Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure.

Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, Penazzato M, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S161-9. doi: 10.1097/QAD.0000000000000236. Review.

PMID:
24849476
8.

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.

Collins SE, Grant PM, Shafer RW.

Drugs. 2016 Jan;76(1):75-98. doi: 10.1007/s40265-015-0515-6. Review.

9.

[Efficacy of dolutegravir in treatment-naïve patients. The SPRING-1, SPRING-2, SINGLE and FLAMINGO trials].

Bernardino JI, Antela A.

Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:14-9. doi: 10.1016/S0213-005X(15)30004-5. Review. Spanish.

PMID:
25858607
10.

[Approaches to antiretroviral therapy in HIV-infected patients with low CD4 lymphocyte counts].

Shakhgildyan VI, Yagodkin MV.

Ter Arkh. 2015;87(11):118-122. doi: 10.17116/terarkh20158711118-122. Review. Russian.

PMID:
26821429

Supplemental Content

Support Center